Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals.Vaccination and monoclonal antibody therapies induce neutralizing antibodies. Thisneutralizing power is recognized as a correlate of protection against a new infection.This study aims to describe the neutralizing power of serum and nasal antibodies overtime, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
This is a monocentric, longitudinal, descriptive study aiming to measure and describe the
evolution of the humoral immune response (serum and nasal) to SARS-CoV-2 and MPXV,
following any vaccination or administration of monoclonal antibodies. Samples are
collected over a maximum 60-month period per participant to assess the durability of
neutralizing activity.
Other: Sample collection (blood and optional nasal swab)
Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots
analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at
Institut Pasteur
Inclusion Criteria:
- Adults (≥18 years)
- Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines
or monoclonal antibodies
- Patients have provided written informed consent
Exclusion Criteria:
- Persons under guardianship or curatorship
- Persons under legal protection,
- Persons persons deprived of liberty
- Persons not affiliated to a social security scheme
- Pregnant or breastfeeding women
CHU Orléans
Orléans, France
Investigator: Thierry PRAZUCK, Dr
Contact: 0238229593
thierry.prazuck@chu-orleans.fr
Investigator: Thierry PRAZUCK, Dr
Thierry PRAZUCK, Dr
0238229593 - +33
thierry.prazuck@chu-orleans.fr
Thierry PRAZUCK, Dr, Principal Investigator
CHU Orléans